Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced a strategic expansion oppor ...

Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indicationBRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an announcement that underscores a broader story: a multi-platform biotech pipeline built for durability across se ...

S-1 1 artl_s1.htm FORM S-1 As filed with the Securities and Exchange Commission on March 24, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Nevada 7389 33-1220924 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

S-1/A 1 artl_s1a.htm FORM-S-1/A As filed with the Securities and Exchange Commission on March 24, 2026 Registration No. 333-294506 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 7389 33-1220924 (I ...

S-1/A 1 artl_s1a.htm FORM-S-1/A As filed with the Securities and Exchange Commission on March 23 , 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Primary Standard Industrial Classification Code Number) Registration No. 333- 294506 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 7389 33-1220924 ...

March 2026 Corporate Presentation Nasdaq:ARTL Pioneering the Science of Lipid Signaling Modulation to Develop Novel Therapeutics Forward Looking Statements Artelo Biosciences, Inc. (the "Company") cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: those rela ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) S-1 1 artl_s1.htm FROM-S-1 As filed with the Securities and Exchange Commission on March 20, 2026 Registration No. 333- (Primary Standard Industrial Classification Code Number) Nevada 7389 33-1220924 (I.R.S. Employer Identification ...

ART27.13 is a peripherally selective synthetic cannabinoid.Glaucoma Study Collaboration Advances ART27.13 DevelopmentArtelo has entered into a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust to explore ART27.13’s effects on intraocular pressure in patients with glaucoma.The study, funded by Glaucoma UK and the HSC R&D Division, is set to enroll its first patient in the second quarter of 2026, marking a pivotal step in expanding ART27.13’s clinical potential.Th ...

DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants ...

Core Insights - Artelo Biosciences is entering the ophthalmology market with a clinical study for ART27.13 targeting glaucoma patients, backed by Glaucoma UK and HSC R&D Division, with first enrollment expected in Q2 2026 [1][2][7] Industry Overview - The global glaucoma market was valued at USD 9.46 billion in 2025 and is projected to reach USD 16.31 billion by 2033, growing at a compound annual growth rate of 7.05% [2] - Approximately 145.9 million people were affected by glaucoma in 2021, expected to rise to 166 million by 2026 [2] - In the U.S., 4.2 million adults had glaucoma in 2022, projected to increase to 6.3 million by 2050 [2] Company Strategy - Artelo's entry into the glaucoma space represents a significant diversification of its pipeline without requiring dilutive equity financing [1][7] - The investigator-sponsored trial model allows Artelo to maintain strategic control and data rights while reducing financial burdens [7] Product Differentiation - ART27.13 is a synthetic cannabinoid receptor agonist that modulates intraocular pressure (IOP) without central nervous system side effects, targeting CB2 receptors for anti-inflammatory and neuroprotective effects [5][6] - Current standard treatments primarily focus on lowering IOP, leaving neuroprotective needs unaddressed, highlighting the opportunity for ART27.13 [4][5] Clinical Development - The study will be led by Professor Augusto Azuara-Blanco at Queen's University Belfast, focusing on the effects of ART27.13 on IOP [7] - The cross-over study design enhances statistical power and reduces required enrollment numbers [7] Pipeline and Intellectual Property - ART27.13 is not limited to glaucoma; it has shown positive interim Phase 2 data in cancer-related anorexia, indicating its broader therapeutic potential [8] - Artelo has received a Notice of Allowance from the European Patent Office for ART27.13, extending patent protection through December 2041 [9] Key Milestones - First patient enrollment in the glaucoma pilot study is expected in Q2 2026 [10] - Ongoing Phase 2 CAReS trial for cancer-related anorexia [10] - European patent protection for ART27.13 commercial formulation through 2041 [10]